Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230258 | 0.83 | PDE4A (0.31) | PDE4ANPC1RAB9A | |
| SCHEMBL4520765 | 0.81 | GABRR1 (0.41) | PDE4ALMNASMN1; SMN2KMT2A | |
| SCHEMBL23374468 | 0.79 | HTT (0.34) | PDE4ALMNASMN1; SMN2HTT | |
| SCHEMBL1808064 | 0.79 | PDE4A (0.33) | PDE4ALMNASMN1; SMN2 | |
| Acetic Acid SCHEMBL18956025 | 0.76 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL28133648 | 0.75 | MAPKAPK2 (0.35) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL16352669 | 0.75 | ALDH1A1 (0.40) | LMNASMN1; SMN2HTTTDP1NPC1 | |
| SCHEMBL13201540 | 0.75 | NPSR1 (0.42) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL4019648 | 0.75 | MAPKAPK2 (0.35) | SMN1; SMN2TDP1NPC1RAB9AKMT2A | |
| SCHEMBL27634983 | 0.73 | SMARCA2 (0.34) | TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | PDE4A 564/4885LMNA 4043/4885SMN1; SMN2 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.